May 28, 2024
Accelerated Ovarian Failure AOF mouse model: a model of transitional menopause
- Roberta Marongiu1,2
- 1Department of Neurological Surgery, Weill Cornell Medical College, New York, NY 10065;
- 2Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA
Protocol Citation: Roberta Marongiu 2024. Accelerated Ovarian Failure AOF mouse model: a model of transitional menopause. protocols.io https://dx.doi.org/10.17504/protocols.io.yxmvmnkbng3p/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: January 25, 2022
Last Modified: September 23, 2024
Protocol Integer ID: 57412
Keywords: ASAPCRN, accelerated ovarian failure aof mouse model, ovarian failure aof mouse model, ovarian hormone loss, effects of ovarian hormone loss, accelerated ovarian failure mouse model, hormonal changes of the human menopause process, animal model of menopause, human menopause process, deplete mouse ovary, assessment of ovarian follicle depletion, model of transitional menopause, human menopause, accelerated ovarian failure, menopause phase, ovarian follicle depletion, menopause, induced mouse model of perimenopaus, ovarian failure, transitional menopause, estrogen, hormonal change, low estrogen level, hormone fluctuation, ovariectomy, neural estrogen, presence of ovarian tissue, ovarian tissue, characterization of neural estrogen, androgen, perimenopaus, aging model, female mice, aging, including erratic estrous cycle, pressor angiotensin ii hypertension in female mice, novel model of aof, erratic estrous cycle, aof model, ovx model, endocrinology, induced mouse model, aof, follicle, primary rodent model
Funders Acknowledgements:
Aligning Science Across Parkinson's
Grant ID: 020608
Abstract
Until recently, aging and ovariectomy (OVX) have been the primary rodent models available to examine effects of ovarian hormone loss. These models fail to adequately recapitulate the hormonal changes of the human menopause process. The intact aging model fails to achieve very low estrogen levels at post-menopause, and the OVX model lacks a peri-menopause phase. Conversely, the novel model of AOF successfully replicates the human peri- and post-menopause stages, including erratic estrous cycles and hormone fluctuations, followed by undetectable estrogen levels[1, 2]. In the AOF model, the ovotoxin 4-vinylcyclohexene diepoxide (VCD, Sigma-Aldrich) is injected (130 mg/kg in 0.5% dimethyl sulfoxide in sesame oil; 5 days/week for 3 weeks; i.p.) in mice which induces selective depletion of ovarian primary and primordial follicles[3]. Previous studies from the Milner lab and other groups confirmed that VCD administration does not negatively affect peripheral tissues nor crosses the blood-brain barrier [1, 2]. In addition to reducing confounds associated with surgical manipulations, the AOF model maintains the presence of ovarian tissue which importantly parallels to human menopause. Based on assessment of ovarian follicle depletion and responses of plasticity markers in brain areas known to be estrogen responsive, timepoints for pre-, peri- and post-AOF have been established [1-4].Timepoints in the AOF model include peri-AOF (>58 days) and post-AOF (>139 days) corresponding to human peri-and post-menopause respectively [1-5].
References
1.Van Kempen, T.A., et al., Characterization of neural estrogen signaling and neurotrophic changes in the accelerated ovarian failure mouse model of menopause. Endocrinology, 2014. 155(9): p. 3610-23.
2.Van Kempen, T.A., T.A. Milner, and E.M. Waters, Accelerated ovarian failure: a novel, chemically induced animal model of menopause.Brain Res, 2011. 1379: p. 176-87.
3.Lohff, J.C., et al., Effect of duration of dosing on onset of ovarian failure in a chemical-induced mouse model of perimenopause. Menopause, 2006. 13(3): p. 482-8.
4.Mayer, L.P., et al., The follicle-deplete mouse ovary produces androgen. Biol Reprod, 2004. 71(1): p. 130-8.
5.Marques-Lopes, J., et al., Redistribution of NMDA Receptors in Estrogen-Receptor-beta-Containing Paraventricular Hypothalamic Neurons following Slow-Pressor Angiotensin II Hypertension in Female Mice with Accelerated Ovarian Failure. Neuroendocrinology, 2017. 104(3): p. 239-256.
Materials
Reagents:
DMSO
sesame oil
ovotoxin 4-vinylcyclohexene diepoxide (VDC)Merck MilliporeSigma (Sigma-Aldrich)Catalog #94956
Ovotoxin 4-vinylcyclohexene diepoxide (VDC) preparation
2h 30m
Determine the number of mice to treat with VCD to calculate how much VCD is needed each day.
Weigh all the mice and obtain an average weight at least once a week for the duration of the VCD treatment. This works only if mice have very similar weighs (+/- a few grams around the average). It is recommended to use the high end of variation for calculations to make sure the heaviest mice get enough VCD.
In the chemical hood, measure volume of VCD from new vial.
Calculate how much sesame oil to add to the VCD vial in order to prepare the working solution (130 mg/kg).
Add sesame oil using a pipet with wide opening trying to avoid bubbles which can affect your volume measurements.
Stir solution for 02:00:00 .
2h
Parafilm well and store it in the fridge.
Every day before use, stir vial for 00:30:00 again.
30m
VDC injections
5 days / week for 3 weeks = i.p injection ; 130 mg/kg in 0.5% dimethyl sulfoxide in sesame oil